Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486955 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL3792450 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL31026188 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL21596445 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL7633965 | 0.98 | CYP1A2 (0.39) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL8085940 | 0.93 | ALDH1A1 (0.36) | CYP1A2GBA1 | |
| SCHEMBL28905056 | 0.90 | S1PR1 (0.40) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL28358596 | 0.88 | CHRNB2 (0.46) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL15958842 | 0.87 | CHRNB2 (0.44) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL18068301 | 0.85 | AR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2916820-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | Rochal Industries, LLC (US) | 2015-09-16 | — | — | EP | claimed |
| US-8852648-B2 | Delivery of biologically-active agents using volatile, hydrophobic solvents | ROCHAL INDUSTRIES, LLP (US) | 2014-10-07 | — | — | US | claimed |
| WO-2014074289-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-15 | — | — | WO | claimed |
| US-20140127320-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-08 | — | — | US | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-2916820-B1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL TECH LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3204037-B1 | COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME | ROCHAL TECH LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-107106663-B | Compositions and kits for enzymatic debridement and methods of use thereof | 罗查尔科技有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3204038-B1 | COMPOSITIONS COMPRISING AMYLASE FOR USE IN THE TREATEMENT OF PRURITUS | ROCHAL TECH LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3204038-A1 | COMPOSITIONS AND KITS FOR TREATING PRURITUS AND METHODS OF USING THE SAME | Rochal Industries, LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057789-A1 | COMPOSITIONS AND KITS FOR TREATING PRURITUS AND METHODS OF USING THE SAME | ROCHAL INDUSTRIES, LLC (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-2916820-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | Rochal Industries, LLC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8852648-B2 | Delivery of biologically-active agents using volatile, hydrophobic solvents | ROCHAL INDUSTRIES, LLP (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2014074289-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20140127320-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-08 | — | — | US | disclosed |
| US-5895717-A | COMPRISING PAIR OF ELECTRICAL CONTACT LAYERS HELD IN SPACED RELATIONSHIP BY ADMIXED COMPOSITE LAYER COMPRISING IMMOBILE OPEN CONNECTED NETWORK OF ORGANIC SEMICONDUCTOR FILLED WITH IONIC SPECIES SOURCE AND HIGH BOILING GEL-FORMING LIQUID | UNIAX CORPORATION (US) | 1999-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | CYP1A2 388/4885CHRNB2 1042/4885CHRNA7 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.